Literature DB >> 19374888

Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type.

Tauheed Ishrat1, Kehkashan Parveen, Mohd Moshahid Khan, Gulrana Khuwaja, M Badruzzaman Khan, Seema Yousuf, Ajmal Ahmad, Pallavi Shrivastav, Fakhrul Islam.   

Abstract

Selenium (Se), a nutritionally essential trace element with known antioxidant potential, protects the brain from oxidative damage in various models of neurodegeneration. Intracerebroventricular-streptozotocin (ICV-STZ) in rats causes impairment of brain glucose and energy metabolism along with oxidative damage and cholinergic dysfunction, and provides a relevant model for sporadic dementia of Alzheimer's type (SDAT). The present study demonstrates the therapeutic efficacy of Se on cognitive deficits and oxidative damage in ICV-STZ in rats. Male Wistar rats were pre-treated with sodium selenite, a salt of Se (0.1 mg/kg; body weight) for 7 days and then were injected bilaterally with ICV-STZ (3 mg/kg), while sham rats received the same volume of vehicle. After two ICV-STZ infusions, rats were tested for memory deficits in passive avoidance and Morris water maze (MWM) tests and then were sacrificed for biochemical and histopathological assays. ICV-STZ-infused rats showed significant loss in learning and memory ability, which were significantly improved by Se supplementation. A significant increase in thio-barbituric acid reactive species (TBARS), protein carbonyl (PC) and a significant decrease in reduced glutathione (GSH), antioxidant enzymes (glutathione peroxidase [GPx] and glutathione reductase [GR]) and adenosine triphosphate (ATP) in the hippocampus and cerebral cortex and choline acetyltransferase (ChAT) in hippocampus were observed in ICV-STZ rats. Se supplementation significantly ameliorated all alterations induced by ICV-STZ in rats. Our study reveals that Se, as a powerful antioxidant, prevents cognitive deficits, oxidative damage and morphological changes in the ICV-STZ rats. Thus, it may have a therapeutic value for the treatment of SDAT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19374888     DOI: 10.1016/j.brainres.2009.04.010

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  45 in total

1.  Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models.

Authors:  Janet van Eersel; Yazi D Ke; Xin Liu; Fabien Delerue; Jillian J Kril; Jürgen Götz; Lars M Ittner
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

Review 2.  Reactive oxygen species in the regulation of synaptic plasticity and memory.

Authors:  Cynthia A Massaad; Eric Klann
Journal:  Antioxid Redox Signal       Date:  2010-10-28       Impact factor: 8.401

Review 3.  Streptozotocin Intracerebroventricular-Induced Neurotoxicity and Brain Insulin Resistance: a Therapeutic Intervention for Treatment of Sporadic Alzheimer's Disease (sAD)-Like Pathology.

Authors:  Pradip K Kamat; Anuradha Kalani; Shivika Rai; Santosh Kumar Tota; Ashok Kumar; Abdullah S Ahmad
Journal:  Mol Neurobiol       Date:  2015-08-23       Impact factor: 5.590

4.  Drotaverine Inhibitor of PDE4: Reverses the Streptozotocin Induced Alzheimer's Disease in Mice.

Authors:  Samra Nazir; Fareeha Anwar; Uzma Saleem; Bashir Ahmad; Zohaib Raza; Maham Sanawar; Artta Ur Rehman; Tariq Ismail
Journal:  Neurochem Res       Date:  2021-04-20       Impact factor: 3.996

5.  Treadmill Exercise Exerts Neuroprotection and Regulates Microglial Polarization and Oxidative Stress in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease.

Authors:  Yujiao Lu; Yan Dong; Donovan Tucker; Ruimin Wang; Mohammad Ejaz Ahmed; Darrell Brann; Quanguang Zhang
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

6.  Krüppel-like factor 8 ameliorates Alzheimer's disease by activating β-catenin.

Authors:  Ran Yi; Benwei Chen; Jing Zhao; Xiaorong Zhan; Liming Zhang; Xiaomin Liu; Qi Dong
Journal:  J Mol Neurosci       Date:  2013-10-11       Impact factor: 3.444

7.  Neuroprotective effects of Bacopa monnieri in experimental model of dementia.

Authors:  Neetu Saini; Devinder Singh; Rajat Sandhir
Journal:  Neurochem Res       Date:  2012-06-15       Impact factor: 3.996

8.  A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse).

Authors:  Yanxing Chen; Zhihou Liang; Julie Blanchard; Chun-Ling Dai; Shenggang Sun; Moon H Lee; Inge Grundke-Iqbal; Khalid Iqbal; Fei Liu; Cheng-Xin Gong
Journal:  Mol Neurobiol       Date:  2012-11-14       Impact factor: 5.590

Review 9.  What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer's disease, about the therapeutic strategies in Alzheimer's research.

Authors:  Melita Salkovic-Petrisic; Ana Knezovic; Siegfried Hoyer; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2012-08-12       Impact factor: 3.575

10.  Bacopa monniera ameliorates cognitive impairment and neurodegeneration induced by intracerebroventricular-streptozotocin in rat: behavioral, biochemical, immunohistochemical and histopathological evidences.

Authors:  M Badruzzaman Khan; Muzamil Ahmad; Saif Ahmad; Tauheed Ishrat; Kumar Vaibhav; Gulrana Khuwaja; Fakhrul Islam
Journal:  Metab Brain Dis       Date:  2014-07-19       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.